Table 3.

Univariate Analysis of the Prognostic Factors of Survival in Patients with NSCLC

Variable	Relapse-Free Survival		Overall Survival
HR (95% CI)	P-value	HR (95% CI)	P-value
Gender
(Male vs female)	0.964(0.548–1.698)	0.900	0.671(0.358–1.258)	0.213
Age
(≥60 vs <60)	0.690(0.410–1.162)	0.163	0.755(0.437–1.308)	0.316
Smoke status
(Yes vs No)	1.642(0.931–2.899)	0.087	1.555(0.852–2.836)	0.150
Pathology
(Non-adenocarcinoma vs adenocarcinoma)	0.885(0.528–1.484)	0.644	0.968(0.561–1.670)	0.906
Grade
(G3 vs G1-G2)	0.990(0.692–1.417)	0.957	1.096(0.757–1.586)	0.629
T stage
(>5cm vs ≤5cm)	1.480(0.841–2.607)	0.174	1.465(0.804–2.671)	0.212
Lymphatic metastasis
(Yes vs No)	2.362(1.405–3.970)	0.001*	3.379(1.933–5.907)	<0.001*
Vessel invasion
(Yes vs No)	0.840(0.205–3.448)	0.809	1.038(0.252–4.272)	0.959
Tumor stage
(III vs I-II)	3.710(2.137–6.440)	<0.001*	4.386(2.468–7.792)	<0.001*
BTLA expression
(Positive vs negative)	1.763(1.048–2.965)	0.033*	1.693(0.979–2.929)	0.060
PD-1 expression
(Positive vs Negative)	1.414(0.843–2.373)	0.189	1.585(0.917–2.739)	0.099
PD-L1 expression
(Positive vs negative)	1.868(1.107–3.153)	0.019*	1.788(1.033–3.097)	0.038*
TILs
(High vs low-medium)	0.753(0.537–1.056)	0.101	0.759(0.531–1.083)	0.129

Note: *Stands for the value of p < 0.05.

Abbreviations: BTLA, B and T lymphocyte attenuator; PD-1, programmed death-1; PD-L1, programmed death ligand-1; TILs, tumor-infiltrating lymphocytes; HR, hazard ratio; CI, confidence interval.